Lp-PLA2

Lp-PLA2

Abbreviation for lipoprotein-associated phospholipase 2.
References in periodicals archive ?
A recent publication in the Journal of Medical Economics demonstrated the use of MPO testing along side of LP-PLA2 and hsCRP and in combination with standard lipid testing could reduce heart attacks and strokes by approximately 10% compared to traditional cholesterol testing alone, not only saving lives but also hundreds of millions of healthcare dollars.
The FDA reviewed data from the Lp-PLA2 Activity study, a sub-study from the National Institute of Health-sponsored Reasons for Geographic and Racial Differences in Stroke (REGARDS) project, which used the test in about 4,600 adults aged 45-92 years; 42% were men, 58% were women, 41.
The PLAC Test for Lp-PLA2 Activitymeasures the activity of lipoprotein-associated phospholipase A2 (Lp-PLA2) in a patient s blood.
Biomarker Evidence for effect on CVD in women Apo A-1 Yes Apo B-100 Yes Lp(a) Yes Lp-PLA2 Yes BNP/NT-proBNP Yes (but not well studied) High-sensitivity Yes troponin Genetic markers Yes CAC Yes Biomarker Improved prediction Improved prediction in populations of in women alone men and women Apo A-1 No No Apo B-100 No No Lp(a) No No Lp-PLA2 No No BNP/NT-proBNP Unclear (studied but Not tested results mixed) High-sensitivity Yes Yes, for CHD troponin Genetic markers Unclear (studied but No results mixed) CAC Yes Not tested
Darapladib is designed to prevent heart attacks and strokes in a completely different way from cholesterol-lowering drugs by targeting an enzyme called Lp-PLA2 that is linked to artery-clogging plaques.
Adamson will present data that indicates the inhibition of Lp-PLA2 in a preclinical model of hyperglycemia induced retinal vascular leak can prevent breakdown of the inner BRB.
There are many clinical trials around the world showing that hs-CRP is a better independent predictor of heart attack and stroke than Lp-PLA2, however Lp-PLA2 is a more specific biomarker of vascular inflammation than hs-CRP: it's more likely to be related to vascular inflammation as opposed to general inflammation such as arthritis.
Significant scientific and clinical evidence support the efficacy and safety of ethyl-EPA in reducing triglyceride levels and other important lipid and inflammation biomarkers, including Apo-B, non-HDL-C, Total-Cholesterol, VLDL-C, Lp-PLA2, and hs-CRP without increasing LDL-C.
A meta-analysis of published studies has shown that Lp-PLA2 is an independent predictor of coronary heart disease events and stroke.
The current study was focused on two biomarkers that have been extensively studied in cardiovascular disease - C-reactive protein (CRP) and N-terminal pro-B-type natriuretic peptide (N-BNP) - and four that recently have been identified as relating to cardiovascular risk - Cystatin C, Lp-PLA2, MR-proADM and MR-proANP.
Lp-PLA2 is a pro-inflammatory enzyme secreted by macrophages that hydrolyzes oxidized phospholipids to yield potentially proatherogenic particles and appears to be a specific marker of plaque inflammation.